|
Howard P.
Greisler, M.D.
Professor, Department of Surgery
Division of Peripheral and Vascular Surgery
Joint Professor,
Department of Cell
Biology, Neurobiology and Anatomy |
|
- B.A., Psychology, 1971. University of Pennsylvania, Philadelphia, PA
- M.D., Hershey Medical Center, 1975. Penn State University
- Fellowships, Vascular Surgery and Transplantation Surgery, 1980-1981.
Columbia-Presbyterian Medical Center, New York, N.Y.
|
|
Current
Interests |
| Intimal hyperglasia, growth factors, tissue engineering,
smooth muscle cells, endothelial cells |
Laboratory Focus |
| Our laboratory focuses on the role of growth factors as mediators of the vascular smooth
muscle cell proliferation central to atherogenesis and to restenosis following clinical
interventions and uses principles of tissue engineering to deliver SMC growth inhibitors
and/or endothelial cell mitogens to inhibit myointimal hyperplasia and to induce
endothelialization. Our current ongoing studies include local delivery systems for a
battery of recombiant FGF mutants designed for greater EC specificity, the development of
novel bioresorbable polymers to induce differential growth factor synthesis by
phagocytizing macrophages, he delivery of antisense oligonucleotides and of chimeric
mitotoxins to selectively inhibit proliferating SMC’s and the seeding of unmodified
and genetically modified ECs onto both de-endothelialized arteries and onto vascular
grafts. Both cell culture and animal models are used to test efficacy while cell responses
are investigated by histologic, biochemical and molecular analyses.
|
Publications |
| Kwon S, Xue L, Tassiopoulos AK,
GREISLER HP: Chemotaxis of Canine Endothelial Cells and Smooth Muscle
Cells using an Under-Fibrin Glue Assay, submitted to J Vasc Surg.
2001. |
|
Xue L, Shireman P,
Woloson S, Tassiopoulos AK, Haudenschild C, Kim DU, GREISLER HP:
Fibrin hydrogel based VEGF delivery for acceleration of arterial re-endothelialization,
submitted to Journal of Surgical Research 2002. |
|
Xue L, GREISLER HP:
Angiogenic effect of fibroblast growth factor-1 and vascular endothelial
growth factor and their synergism in a novel in vitro quantitative
fibrin-based three-dimensional angiogenesis system, Surgery
132(2); 259-267, 2002. |
|
GREISLER HP, Regulated in vivo remodeling, Ann NY
Acad Sci June; 961:309-11, 2002. |
| Erzurum V, Xue, L, Burgess W,
GREISLER HP: The R136K Fibroblast Growth Factor-1 Mutant Induces
Heparin-Independent Migration of Endothelial Cells Through Fibrin Glue. J
Vasc Surg. , 37(5); 1075-1081, 2003. |
|
Xue, Lian and
GREISLER HP, Invited Review: Biomaterials in the Development and future
of Vascular Grafts, J Vasc Surg.; 37 (2), 472 – 481, 2003. |
| Laredo J, Xue L, Husak V, Ellinger
J, GREISLER HP: Silyl-heparin adsorption improves the in vivo
thromboresistance of carbon-coated polytetrafluoroethylene vascular grafts,
Amer J Surgery ; 186 (5) 556-560, 2003. |
| Leon L, GREISLER HP: Vascular
Grafts, Expert Rev. Cardiovasc. Ther ; 1(14) 581-594, 2003. |
| Xue L, Sharma R, Cochran K,
Tassiopoulos A, Jara-Almonte J, Cromack K, Zage J, Wilding N, Tarcha P,
GREISLER HP: The Effect of the Rapamycin Derivative ABT-578 on Canine
Smooth Muscle Cell and Endothelial Cell Proliferation, Preclinica,
, Nov-Dec, 2(6), 2004. |
| Laredo J, Xue L, Husak V, Ellinger
J, Singh G, Zamora P and GREISLER HP: Silyl-heparin bonding improves
the patency and in vivo thromboresistance of carbon-coated
polytetrafluoroethylene vascular grafts. J Vasc Surg ; 39(5)
1059-65, 2004. |
| GREISLER HP: Induction of
Endothelialization of Tissue-Engineered Cardiovascular Constructs via In
Vivo Angiogenesis in Post Implant Remodeling. Atherosclerosis XIII.
Volume 1262:115-117. May 2004. |
|
Brey E, Uriel S,
GREISLER HP, Patrick C, McIntire L: Therapeutic neovascularization:
contributions from bioengineering. Tissue Engineering. In Press.
September 2004. |
| Brewster LP, Brey EM, Tassiopoulos
AK, Xue L, Maddox E, Armistead D, Burgess WH and GREISLER HP:
Heparin-independent mitogenicity in and endothelial and smooth muscle cell
chimeric growth factor (S130K-HBGAM) Amer Jour Surg ; 188 (5) 575-579,
2004. |
Brewster LP, Brey EM, Tassiopoulos AK, Xue
L, Maddox E, Armistead D, Burgess WH and
Greisler HP:
Heparin-independent mitogenicity in an endothelial and smooth muscle
cell chimeric growth factor (S130K-HBGAM) Amer Jour Surg ; 188
(5) 575-579, 2004.
|
|
Book Chapters |
| Laredo J, GREISLER HP (2003)
Future Perspective: Tissue engineering? - The World of Mesh Meshes: Benefits
and Risks. Schumpelick V, Nyhus LM, Eds; Springer-Verlag France: Paris. |
| GREISLER HP, (2003)
Biomolecules, WTEC Panel Report of Tissue Engineering Research. Academic
Press, San Diego California, 2003. |
| Laredo J, Xue L, GREISLER HP (2004)
Vascular Grafts: Host Interactions. In Encyclopedia of Biomaterials and
Biomedical Engineering, Wuek G, Bowlin G, Eds; Marcel Dekker: New York. (In
Press 2004) |
| Laredo J, Xue L, GREISLER HP (2004)
Vascular Grafts: Development Strategies. In Encyclopedia of Biomaterials and
Biomedical Engineering, Wuek G, Bowlin G, Eds; Marcel Dekker: New York. (In
Press 2004). |
|
